1. Home
  2. PRHI vs MRKR Comparison

PRHI vs MRKR Comparison

Compare PRHI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRHI

Presurance Holdings Inc.

HOLD

Current Price

$4.56

Market Cap

18.7M

Sector

Finance

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.12

Market Cap

18.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRHI
MRKR
Founded
2009
1999
Country
United States
United States
Employees
12
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.7M
18.7M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
PRHI
MRKR
Price
$4.56
$1.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
2.8K
40.3K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.81
52 Week High
$6.40
$2.46

Technical Indicators

Market Signals
Indicator
PRHI
MRKR
Relative Strength Index (RSI) 42.70 36.37
Support Level $4.55 $1.05
Resistance Level $5.84 $1.54
Average True Range (ATR) 0.31 0.08
MACD -0.15 -0.00
Stochastic Oscillator 17.33 29.67

Price Performance

Historical Comparison
PRHI
MRKR

About PRHI Presurance Holdings Inc.

Presurance Holdings Inc is an insurance holding company that markets and services product offerings through specialty personal insurance lines of business. Through its personal insurance lines, it offers homeowners insurance and dwelling fire insurance products to individuals in several states. The specialty homeowners insurance product line is comprised of low-value dwelling insurance tailored for owners of lower valued homes, which it offers in Texas, Illinois and Indiana. Through commercial insurance lines, it offers coverage for both commercial property and commercial liability and also offered coverage for commercial automobiles and workers' compensation. Its revenues are derived from premiums earned from insurance operations.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: